Table 1. Demographic and clinical characteristics of the study patients at hospitalization.
| Central NPSLE (n = 42) | Peripheral NPSLE (n = 5) | Non-NP SLE (n = 49) | SLE-Surgical (n = 16) | SLE-septic meningitis (n = 6) | Non-autoimmune (n = 25) | |
| Age, years A | 31.5±11.6 | 23.8±6.1 | 30.7±12.0 | 37.8±9.8 | 29.7±10.3 | 37.5±15.3 |
| Male/female | 7/35 | 0/5 | 4/45 | 2/14 | 0/6 | 6/19 |
| SLE duration, years | 3.9±4.4 | 1.8±2.4 | 8.8±6.5B | 8.8±7.2C | 3.2±3.8 | – |
| SLE criteria, No. | 5.4±2.1 | 6±3.2 | 5.0±2.4 | 6.1±2.0 | 5.3±1.5 | – |
| SLEDAI–2K score, at baseline | 14.9±9.4 | 13.2±8.7 | 11.5±7.9 | 3.8±1.5B | 10.6±6.0 | – |
| SLEDAI–2K score, at 6 months | 5.4±5.8 | 4.0±6.9 | 5.9±6.6 | – | – | – |
| SLICC/ACR DI score | 0.7±1.2 | 0.4±0.9 | 0.4±0.8 | 0.8±0.4 | 0.3±0.5 | – |
| Prednisone use, % | 91 | 100 | 92 | 6.3B | 100 | – |
| Prednisone dose, mg/day | 44.7±24.3 | 52±13.0 | 41.7±22.5 | – | 55±12.2 | – |
| Immunosuppressants use, % | 48 | 100 | 71D | 25 | 17B | – |
A
Except where indicated otherwise, values are the mean±SD. SLE = systemic lupus erythematosus; NPSLE = neuropsychiatric SLE; SLEDAI-2K = Systemic Lupus Erythematosus Disease Activity Index 2000 update; SLICC/ACR DI = Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index.
B
P<0.001 versus Central NPSLE
C
P = 0.003 versus Central NPSLE
D
P = 0.02 versus Central NPSLE